12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Phase III ongoing

Curacyte said an independent DMB recommended continuation of the placebo-controlled, European Phase III PHOENIX trial based on interim analysis of safety and mortality data from half of the planned 454 patients....

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >